$ATEX

Marquez Elena sold $341K of ATEX

Marquez Elena (Chief Financial Officer) sold 4,291 shares of Anterix Inc. (ATEX) at $79.50 ($0.34M total) on 2026-06-17.

Original reporting
SEC EDGAR · Marquez Elena
Published Jun 18, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings; it does not include any company performance, guidance, or regulatory/legal development.

02

Market read

Traders may monitor for clustering of insider activity, but this single sale is unlikely to drive a sustained repricing without corroborating fundamentals.

03

What to watch

Insider sales often reflect diversification, tax planning, or scheduled liquidity needs; without additional context (e.g., other insider buys/sales, guidance changes), directional inference is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-18 for a 2026-06-17 sale

Background

This is an SEC Form 4 insider transaction disclosure for Anterix (ATEX) by CFO Marquez Elena.

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

CFO Marquez Elena filed a Form 4 selling 4,291 shares of Anterix (ATEX) at $79.50 on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect is typically short-lived unless paired with other negative disclosures.

Evidence & confidence

The filing is an open-market sale with no 10b5-1 plan stated; however, insider sales alone are usually not a strong directional catalyst without accompanying guidance, enforcement, or material corporate events.

Market effects

Minimal—single insider transaction in a non-sector-wide context.

None indicated.

None indicated.

Counterpoint

Because the sale is by the CFO and explicitly notes no 10b5-1 plan, some traders may interpret it as a stronger signal than typical insider sales—though the article provides no rationale or follow-on actions.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure (ATEX).

  • Marquez Elena

    Chief Financial Officer who sold 4,291 shares on 2026-06-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2